VaxInnate wins $597K grant for Dengue-fever vaccine
VaxInnate, a Cranbury, N.J., vaccine-focused biotech, received a $597,000 small-business innovation grant from the NIH to support work on a vaccine against Dengue fever, a mosquito-borne viral disease. VaxInnate’s primary focus is on new influenza vaccines that are designed to stimulate “toll-like receptors” that can produce a more robust immune response. The company’s description of its technology is here.
Next Story: Phone service Jangl lands four new partners
Previous Story: TranS1 aims to relieve lower-back pain with $80.5M IPO
About the Author, David P. Hamilton
David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.
